Pfizer Toekomstige groei

Future criteriumcontroles 2/6

Pfizer zal naar verwachting groeien in winst en omzet met respectievelijk 17.1% en 0.8% per jaar. De winst per aandeel zal naar verwachting groeien met 17.1% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting 17% zijn.

Belangrijke informatie

17.1%

Groei van de winst

17.1%

Groei van de winst per aandeel

Pharmaceuticals winstgroei	23.6%
Inkomstengroei	0.8%
Toekomstig rendement op eigen vermogen	17.0%
Dekking van analisten	Good
Laatst bijgewerkt	06 Nov 2024

Recente toekomstige groei-updates

Pfizer Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Nov 01

Recent updates

Pfizer Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Nov 01

Winst- en omzetgroeiprognoses

NYSE:PFE - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2026	63,625	12,185	16,882	19,858	20
12/31/2025	62,929	11,234	16,122	18,278	22
12/31/2024	62,625	9,222	8,599	16,404	21
9/29/2024	59,375	4,274	8,227	11,263	N/A
6/30/2024	55,166	-2,593	4,810	8,005	N/A
3/31/2024	54,889	-288	5,106	8,578	N/A
12/31/2023	58,496	2,134	4,793	8,700	N/A
10/1/2023	69,274	10,469	8,178	12,042	N/A
7/2/2023	78,420	21,494	10,665	14,560	N/A
4/2/2023	93,154	29,035	20,206	23,938	N/A
12/31/2022	100,330	31,366	26,031	29,267	N/A
10/2/2022	99,878	29,953	23,362	26,599	N/A
7/3/2022	101,275	29,481	28,440	31,454	N/A
4/3/2022	92,433	25,410	31,783	34,583	N/A
12/31/2021	81,288	22,413	29,869	32,580	N/A
10/3/2021	68,877	19,485	29,769	32,291	N/A
7/4/2021	55,119	12,236	21,141	23,552	N/A
4/4/2021	46,084	9,032	13,477	15,808	N/A
12/31/2020	41,651	6,630	12,177	14,403	N/A
9/27/2020	32,334	212	10,512	12,547	N/A
6/28/2020	34,737	6,977	12,777	14,967	N/A
3/29/2020	38,137	9,427	11,702	14,023	N/A
12/31/2019	40,905	10,707	10,542	12,588	N/A
9/29/2019	53,039	16,211	10,897	13,557	N/A
6/30/2019	53,656	12,638	11,746	14,306	N/A
3/31/2019	53,859	11,464	13,146	15,542	N/A
12/31/2018	40,825	3,824	13,691	15,827	N/A
9/30/2018	53,373	23,808	16,001	18,178	N/A
7/1/2018	53,244	22,545	N/A	17,808	N/A
4/1/2018	52,673	21,746	N/A	17,201	N/A
12/31/2017	52,546	21,305	N/A	16,802	N/A
10/1/2017	52,471	9,791	N/A	15,463	N/A
7/2/2017	52,347	8,308	N/A	15,311	N/A
4/2/2017	52,598	7,281	N/A	15,677	N/A
12/31/2016	52,824	7,198	N/A	16,192	N/A
10/2/2016	53,243	6,270	N/A	15,049	N/A
7/3/2016	52,286	7,036	N/A	15,332	N/A
4/3/2016	50,992	7,615	N/A	15,816	N/A
12/31/2015	48,851	6,948	N/A	14,688	N/A
9/27/2015	47,922	8,366	N/A	15,188	N/A
6/28/2015	48,196	8,913	N/A	14,631	N/A
3/29/2015	49,116	9,200	N/A	14,628	N/A
12/31/2014	49,605	9,085	N/A	17,084	N/A
9/28/2014	50,045	10,461	N/A	17,209	N/A
6/29/2014	50,327	10,370	N/A	18,646	N/A
3/30/2014	50,527	10,994	N/A	18,316	N/A
12/31/2013	51,584	11,339	N/A	17,684	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachte winstgroei PFE ( 17.1% per jaar) ligt boven de spaarquote ( 2.6% ).

Winst versus markt: De winst van PFE ( 17.1% per jaar) zal naar verwachting sneller groeien dan de US markt ( 15.4% per jaar).

Hoge groeiwinsten: De winst van PFE zal naar verwachting groeien, maar niet aanzienlijk.

Omzet versus markt: De omzet van PFE ( 0.8% per jaar) zal naar verwachting langzamer groeien dan de markt US ( 8.9% per jaar).

Hoge groei-inkomsten: De omzet van PFE ( 0.8% per jaar) zal naar verwachting langzamer groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Het rendement op eigen vermogen PFE zal naar verwachting over 3 jaar laag zijn ( 17 %).

Pfizer Toekomstige groei

Future criteriumcontroles 2/6

Belangrijke informatie

Recente toekomstige groei-updates

Pfizer Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Pfizer Inc. Revises Earnings Guidance for the Year 2024

Recent updates

Pfizer Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Pfizer, Inc. and Global Blood Therapeutics, Inc. Sued over Alleged Sickle Cell Drug Side Effects

Upcoming dividend of US$0.42 per share

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Pfizer Delivers Knockout Q3 Earnings Results, But Investors Are Unimpressed

Pfizer Inc. Revises Earnings Guidance for the Year 2024

Pfizer Inc. Announces Advisory Committee on Immunization Practices Recommends PREVNAR 20® (20-Valent Pneumococcal Conjugate Vaccine) for Adults Aged 50 and Older

Pfizer: Activists Clouding A Promising Picture

Pfizer Inc. Announces Election of Mortimer J. Buckley to Its Board of Directors

Second quarter dividend of US$0.42 announced

U.S. FDA Approves Pfizer Inc.’s HYMPAVZI™ (marstacimab-hncq) for the Treatment of Adults and Adolescents with Hemophilia A or B Without Inhibitors

Pfizer Inc. Announces Positive Topline Results from the Final Prespecified Overall Survival Analysis of the TALAPRO-2 Study of TALZENNA®

Pfizer: A Strong Product Pipeline Could Lead To Significant Upside

Starboard Value Wants Pfizer to Make Changes to Turn its Performance Around

Pfizer Intends to Sell About 540 Million Ordinary Shares in Haleon

Pfizer: Growth From Oncology Franchise; Initiate With 'Buy'

There's Reason For Concern Over Pfizer Inc.'s (NYSE:PFE) Price

Pfizer: Undervalued Healthcare Leader Poised For Further Recovery

Pfizer and BioNTech SE Receive Positive CHMP Opinion for Omicron KP.2-Adapted Covid-19 Vaccine in the European Union

Pfizer Inc. to Report Q3, 2024 Results on Oct 29, 2024

Pfizer Announces its BRAFTOVI + MEKTOVI Shows Long-Term Clinically Meaningful Response in Patients with BRAF V600E-Mutant Metastatic Non-Small Cell Lung Cancer

Pfizer Presents Positive Data from Phase 2 Study of Ponsegromab in Patients with Cancer Cachexia

Why Pfizer Investors Should Closely Monitor VAX-31

Pfizer Appoints Elif Aral as Regional President for Middle East, Russia, and Africa (MERA)

Valneva SE and Pfizer Inc. Report Further Positive Phase 2 Booster Results for Lyme Disease Vaccine Candidate

Pfizer: Look Beyond COVID-19 And The Patent Cliffs - Robust Long-Term Tailwinds

Albertsons Companies, Inc. Offers the Latest Monovalent mRNA COVID Vaccines from Pfizer and Moderna Along with the Annual Flu Vaccine

Pfizer Inc. Launches PfizerForAll

Pfizer: Performance Is Improving, But Secular Issues Persist (Rating Upgrade)

Pfizer Inc. and BioNTech SE Receive U.S. FDA Approval & Authorization for Omicron KP.2-Adapted COVID-19 Vaccine

Winst- en omzetgroeiprognoses

Toekomstige groeivoorspellingen analisten

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Ontdek groeibedrijven